Physician profile
Ulrich Specks
NPI 1588643456
$77,273.40
in general payments reported to CMS, 2019-2025
13 companies · $25K in 2025
The $25K reported for 2025 was more than what 96% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,431 · 2020: $900 · 2022: $12K · 2023: $12K · 2024: $25K · 2025: $25K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $62K · Food and Beverage: $468 · Travel and Lodging: $12.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $61,585.46 |
| Food and Beverage | $468.24 |
| Travel and Lodging | $12.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29,904.95 | 2022-2025 | Tavneos |
| Astrazeneca Uk Limited | $27,036.00 | 2020-2025 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $8,277.92 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $5,653.25 | 2019-2025 | Fasenra |
| Alexion Pharmaceuticals, INC. | $3,403.18 | 2025 | |
| Boehringer Ingelheim Pharma Gmbh & Co.Kg | $2,867.97 | 2023 | Ofev |
| Novartis Pharmaceuticals Corporation | $130.13 | 2024 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulrich Specks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.